With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities.
With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities.